22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › 10X GENOMICS INC. › 2024-2025

10X GENOMICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and 10X GENOMICS INC.’s Form 8-K, filed June 5, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 282Asset managers, any item
  • 1,184Fund votes
  • June 3, 2025Meeting date

Results at a glance

Meeting of June 3, 2025: 4 items on 10X GENOMICS INC.’s Form 8-K, filed June 5, 2025: 2 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (14.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore 10X GENOMICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by 10X GENOMICS INC.

These tallies are 10X GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

10X GENOMICS INC. — official shareholder meeting results, meeting held June 3, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sri Kosaraju 189,313,7247,243,542172,526 --19,837,766 96%Passed (calculated)—
Elect Director: Shehnaaz Suliman 168,973,46827,595,026161,298 --19,837,766 86%Passed (calculated)—
2. Ratification of Independent Registered Public Accounting Firm 215,766,816312,396488,346 ---- 99.9%Approved—
3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers 164,321,76532,192,042215,985 --19,837,766 84%Approved—

Source: 10X GENOMICS INC., Form 8-K, filed with the SEC on June 5, 2025 — read the filing on EDGAR.

How asset managers voted at the 10X GENOMICS INC. 2024-2025 meeting

282 asset managers disclosed a vote on at least one 10X GENOMICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Shehnaaz Suliman

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST
FOR: 168,973,468AGAINST: 27,595,026
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Shehnaaz Suliman

10X GENOMICS INC.’s own tally for this item (“Elect Director: Shehnaaz Suliman”): 168,973,468 for, 27,595,026 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 37,993,917 for, 3,482,903 against, 5,725 abstained.

FOR
FOR: 37,993,917AGAINST: 3,482,903ABSTAIN: 5,725
Largest asset managers voting on “Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of st” at 10X GENOMICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,468,4941,745,533 00Mixed
ARK ETF Trust11,685,1430 00For
Vanguard11,146,941921 00For
BlackRock2,235,5700 00For
Capital Group1,452,3000 00For
Charles Schwab0652,941 00Against
AMERICAN BEACON FUNDS256,4310 00For
TIAA0193,983 00Against
Columbia Threadneedle128,5460 00For
Global X0123,044 00Against
Exchange Place Advisors Trust0120,562 00Against
ARK Venture Fund96,7200 00For
Voya095,424 00Against
Morgan Stanley82,0180 00For
Equitable55,37026,354 00Mixed
Pacific Life81,6140 00For
NORTHERN LIGHTS FUND TRUST III78,5230 00For
MASTER INVESTMENT PORTFOLIO77,0140 00For
Lincoln Financial3,41663,860 00Mixed
Nationwide055,973 00Against
SEI050,514 00Against
Invesco050,328 00Against
PACE SELECT ADVISORS TRUST046,308 00Against
T. Rowe Price46,2010 00For
ALGER FUNDS038,365 00Against

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Elect Director: Sri Kosaraju

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 189,313,724AGAINST: 7,243,542
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Sri Kosaraju

10X GENOMICS INC.’s own tally for this item (“Elect Director: Sri Kosaraju”): 189,313,724 for, 7,243,542 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 41,311,794 for, 165,026 against, 5,725 abstained.

FOR
FOR: 41,311,794AGAINST: 165,026ABSTAIN: 5,725
Largest asset managers voting on “Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of st” at 10X GENOMICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,214,0270 00For
ARK ETF Trust11,685,1430 00For
Vanguard11,146,942920 00For
BlackRock2,235,5700 00For
Capital Group1,452,3000 00For
Charles Schwab652,9410 00For
AMERICAN BEACON FUNDS256,4310 00For
TIAA193,9830 00For
Columbia Threadneedle128,5460 00For
Global X123,0440 00For
Exchange Place Advisors Trust120,5620 00For
ARK Venture Fund96,7200 00For
Voya095,424 00Against
Morgan Stanley82,0180 00For
Equitable55,37026,354 00Mixed
Pacific Life81,6140 00For
NORTHERN LIGHTS FUND TRUST III78,5230 00For
MASTER INVESTMENT PORTFOLIO77,0140 00For
Lincoln Financial64,1053,171 00For
Nationwide55,9730 00For
SEI50,5140 00For
Invesco50,3280 00For
PACE SELECT ADVISORS TRUST46,3080 00For
T. Rowe Price46,2010 00For
ALGER FUNDS38,3650 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 13 wordings of this item as funds reported it.

84% Approved · of votes cast

FOR 84%AGAINST
FOR: 164,321,765AGAINST: 32,192,042

Prior year: 83.2% for (June 11, 2024 meeting) ▲ 0.4 pts

Details: description as filed, official tally, votes by 282 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

10X GENOMICS INC.’s own tally for this item (“3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 164,321,765 for, 32,192,042 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at 10X GENOMICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,160,39153,636 00For
ARK ETF Trust11,685,1430 00For
Vanguard11,146,941921 00For
BlackRock158,8802,076,690 00Mixed
Capital Group01,452,300 00Against
Charles Schwab0652,941 00Against
AMERICAN BEACON FUNDS256,4310 00For
TIAA0193,983 00Against
Columbia Threadneedle0128,546 00Against
Global X0123,044 00Against
Exchange Place Advisors Trust0120,562 00Against
ARK Venture Fund96,7200 00For
Voya095,424 00Against
Morgan Stanley082,018 00Against
Equitable081,724 00Against
Pacific Life75,7705,844 00Mixed
NORTHERN LIGHTS FUND TRUST III078,523 00Against
MASTER INVESTMENT PORTFOLIO15,82861,186 00Mixed
Lincoln Financial067,276 00Against
Nationwide055,973 00Against
SEI050,514 00Against
Invesco050,328 00Against
PACE SELECT ADVISORS TRUST046,308 00Against
T. Rowe Price046,201 00Against
ALGER FUNDS038,365 00Against

Fund voting reports, all 59 managers: 35,663,218 for, 5,813,602 against, 5,725 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 240 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at 10X GENOMICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity10,761,3080 00For
Nikko Asset Management Co., Ltd.05,389,611 00Against
BlackRock525,5942,134,291 00Mixed
Two Sigma02,159,053 00Against
UBS02,111,528 00Against
GEODE CAPITAL MANAGEMENT, LLC1,962,5610 00For
RA CAPITAL MANAGEMENT, L.P.01,655,103 00Against
DEERFIELD MANAGEMENT COMPANY, L.P.1,505,5850 00For
Capital Group01,452,300 00Against
State Street1,401,97247,580 00For
Camber Capital Management LP01,000,000 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC0751,273 00Against
Charles Schwab0653,315 00Against
AQR0601,164 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC0525,945 00Against
Sands Capital Alternatives, LLC0481,770 00Against
BOSTON MANAGEMENT & RESEARCH0467,079 00Against
MARSHALL WACE, LLP0439,403 00Against
STATE OF MICHIGAN RETIREMENT SYSTEM0399,413 00Against
ARK Investment Management LLC356,6690 00For
T. Rowe Price0325,693 00Against
Amundi0320,340 00Against
Northern Trust278,55610,852 00For
Vestmark Advisory Solutions, Inc.0285,137 00Against
Morgan Stanley0274,764 00Against

Institutional-manager reports, all 240 managers: 17,675,215 for, 25,639,523 against, 84,291 abstained, 50,939 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 215,766,816AGAINST: 312,396

Prior year: 99.9% for (June 11, 2024 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and

10X GENOMICS INC.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 215,766,816 for, 312,396 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 41,397,442 for, 79,378 against, 5,725 abstained.

FOR
FOR: 41,397,442AGAINST: 79,378ABSTAIN: 5,725
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at 10X GENOMICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,214,0270 00For
ARK ETF Trust11,685,1430 00For
Vanguard11,147,8620 00For
BlackRock2,235,5700 00For
Capital Group1,452,3000 00For
Charles Schwab652,9410 00For
AMERICAN BEACON FUNDS256,4310 00For
TIAA193,9830 00For
Columbia Threadneedle128,5460 00For
Global X123,0440 00For
Exchange Place Advisors Trust120,5620 00For
ARK Venture Fund96,7200 00For
Voya95,4240 00For
Morgan Stanley82,0180 00For
Equitable81,7240 00For
Pacific Life81,6140 00For
NORTHERN LIGHTS FUND TRUST III078,523 00Against
MASTER INVESTMENT PORTFOLIO77,0140 00For
Lincoln Financial67,2760 00For
Nationwide55,9730 00For
SEI50,5140 00For
Invesco50,3280 00For
PACE SELECT ADVISORS TRUST46,3080 00For
T. Rowe Price46,2010 00For
ALGER FUNDS38,3650 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Largest 10X GENOMICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 122,291,837 shares outstanding at the time of that meeting.

Fund voting reports: top 10X GENOMICS INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 9.99%
2ARK ETF Trust 9.56%
3Vanguard 9.12%
4BlackRock 1.83%
5Capital Group 1.19%
6Charles Schwab 0.53%
7AMERICAN BEACON FUNDS 0.21%
8TIAA 0.16%
9Columbia Threadneedle 0.11%
10Global X 0.10%
Institutional-manager reports: top 10X GENOMICS INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 8.80%
2Nikko Asset Management Co., Ltd. 4.41%
3BlackRock 2.18%
4Two Sigma 1.77%
5UBS 1.73%
6GEODE CAPITAL MANAGEMENT, LLC 1.60%
7RA CAPITAL MANAGEMENT, L.P. 1.35%
8DEERFIELD MANAGEMENT COMPANY, L.P. 1.23%
9Capital Group 1.19%
10State Street 1.19%

Reported 10X GENOMICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

10X GENOMICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
ARK Investment Management LLC11,887,396 9.72%Schedule 13G, filed November 4, 2025
Vanguard Group11,118,086 9.09%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)9,893,139 8.09%Form 13F, quarter ended March 31, 2025
Vanguard Portfolio Management6,981,683 5.71%Schedule 13G, filed April 28, 2026
BlackRock6,667,822 5.45%Form 13F, quarter ended March 31, 2025
Nikko Asset Management Americas, Inc.6,009,653 4.91%Schedule 13G, filed August 13, 2025
Sumitomo Mitsui Trust Group, Inc.5,381,219 4.40%Schedule 13G, filed October 27, 2025
Millennium Management5,377,492 4.40%Form 13F, quarter ended March 31, 2025
Amova Asset Management Americas, Inc.5,376,883 4.40%Schedule 13G, filed November 13, 2025
Morgan Stanley2,774,091 2.27%Form 13F, quarter ended March 31, 2025

Percentages above are of 122,291,837 shares outstanding, as reported by 10X GENOMICS INC. on its Form 10-K dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At 10X GENOMICS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 282 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,184 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — 10X GENOMICS INC.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 10X GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10X GENOMICS INC.’s 10-K dated December 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

10X GENOMICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “10X GENOMICS (TXG) 2025 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/10x-genomics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.